New Biotech ETFs, leveraged, ultralong and short

For investors looking for leverage and inverse ETFs in Biotech, ProShares has just announced a couple.

The company is launching two new ETFs with leveraged and inverse exposure to the biotechnology sector, seeking to provide 200% or -200% of the return of the NASDAQ Biotechnology Index:

• Ultra Nasdaq Biotechnology (BIB)
• UltraShort Nasdaq Biotechnology (BIS)

The expense ratio is high at 0.95%. Investors should be aware that leveraged ETFs are money losing in the long term.

BIB's top holdings:

AMGEN INC COM STK	9.59%
TEVA PHARMACEUTICAL ADR	7.78%
GILEAD SCIENCES USD0.001	7.08%
CELGENE CORP COM STK	6.15%
VERTEX PHARMACEUTICAL COM	3.78%
BIOGEN IDEC INC COM STK	2.91%
DENDREON CORP COM STK NPV	2.61%
PERRIGO CO COM STK NPV	2.61%
ALEXION PHARMACEUTICAL	2.53%
GENZYME CORP COM STK	2.42%

 BIS's holdings:

NBI SWAPS	(12,007,790.78)	-	(12,627.42)
Net Other Assets / Cash	-	5,992,293.67	5,992,293.67

---